Search our Database of Scientific Publications and Authors

I’m looking for a

    7975 results match your criteria Psoriatic Arthritis

    1 OF 160

    A two-phase model for chronic disease processes under intermittent inspection.
    Stat Med 2017 Feb 26. Epub 2017 Feb 26.
    Department of Statistics and Actuarial Science, University of Waterloo, 200 University Avenue West, Waterloo, N2L 3G1, ON, Canada.
    A model is developed for chronic diseases with an indolent phase that is followed by a phase with more active disease resulting in progression and damage. The time scales for the intensity functions for the active phase are more naturally based on the time since the start of the active phase, corresponding to a semi-Markov formulation. This two-phase model enables one to fit a separate regression model for the duration of the indolent phase and intensity-based models for the more active second phase. Read More

    Misalignment between physicians and patient satisfaction with psoriatic arthritis disease control.
    Clin Rheumatol 2017 Feb 25. Epub 2017 Feb 25.
    Health Economics & Outcomes Research, Immunology & Dermatology Business Unit, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 07936, USA.
    The main objective of the present study is to evaluate the misalignment between psoriatic arthritis (PsA) patient- and physician-reported satisfaction with PsA control. Data came from the Adelphi Rheumatology Disease Specific Programme, a retrospective, cross-sectional survey of US-based rheumatologists and patients. Physicians provided satisfaction and clinical characteristics on tender joint count, swollen joint count, and percent body surface area (BSA) affected by psoriasis. Read More

    Depression Is Associated with an Increased Risk of Psoriatic Arthritis among Patients with Psoriasis: A Population-Based Study.
    J Invest Dermatol 2017 Feb 18. Epub 2017 Feb 18.
    Department of Community Health Sciences, Cumming School of Medicine, Calgary, Alberta, Canada; Division of Rheumatology, Cumming School of Medicine, Calgary, Alberta, Canada. Electronic address:
    The factors that contribute to the development of psoriatic arthritis (PsA) among patients with psoriasis are not well known; however, systemic inflammation is believed to be important. On the basis of recent laboratory work demonstrating that major depressive disorder (MDD) is associated with increased systemic inflammation, we hypothesized that patients with psoriasis who develop MDD are at increased risk of subsequently developing PsA. We utilized The Health Improvement Network, a primary care medical records database, to identify 73,447 individuals with psoriasis. Read More

    IL-6 Differs from TNF-α: Unpredicted Clinical Effects Caused by IL-6 Blockade in Psoriasis.
    J Invest Dermatol 2017 Mar;137(3):541-542
    Oregon Medical Research Center, Portland, Oregon, USA. Electronic address:
    IL-6 is a pleiotropic proinflammatory cytokine that is elevated in serum and skin lesions of patients with psoriasis. Anti-IL-6 therapies, however, which are effective for rheumatoid arthritis, are either ineffective for psoriasis or can induce new-onset psoriasis-like disease. Fritz et al. Read More

    Important Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative Study.
    Patient 2017 Feb 22. Epub 2017 Feb 22.
    Royal National Hospital for Rheumatic Diseases, Bath, UK.
    Background: Psoriatic arthritis (PsA) is a variable and complex inflammatory condition. Symptoms can compromise physical function, reduce quality of life, and accrue significant health costs. Commonly used patient-reported outcomes largely reflect the professionals' perspective, however it is not known whether they capture what is important to patients. Read More

    Psoriasis and Obesity.
    Dermatology 2017 Feb 23. Epub 2017 Feb 23.
    Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Hellerup, Denmark.
    Psoriasis is a common chronic inflammatory skin disease with a complex pathogenesis consisting of a genetic component, immune dysfunction, and environmental factors. It is associated with numerous comorbidities including psoriatic arthritis, cardiovascular disease, metabolic syndrome, and obesity. Evidence suggests that obesity is a risk factor for incident psoriasis, aggravates existing psoriasis, and that weight reduction may improve the severity of psoriasis in overweight individuals. Read More

    Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis.
    An Bras Dermatol 2017 Jan-Feb;92(1):21-25
    Department of Rheumatology of the Pontifícia Universidade Católica do Rio Grande do Sul (PUCRS) - Porto Alegre (RS), Brazil.
    Background:: The nail involvement in psoriasis is related to psoriatic arthritis and may represent a predictor of the disease.

    Objectives:: To analyze, through nail clipping, clinically normal and dystrophic nails of patients with cutaneous psoriasis and psoriatic arthritis.

    Methods:: This is a cross-sectional multicenter study, conducted between August 2011 and March 2012. Read More

    Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
    PLoS One 2017 22;12(2):e0169830. Epub 2017 Feb 22.
    Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway.
    Background: Pentraxin 3 is proposed to be a marker of inflammation and cardiovascular risk, but its role in inflammatory rheumatic diseases (IRDs) is still uncertain. Therefore, we wanted to examine if anti-rheumatic treatment reduced serum PTX3 (s-PTX3) levels in IRDs, and if s-PTX3 levels were related to other markers of inflammation and to endothelial function (EF).

    Methods: We examined s-PTX3, EF and established inflammatory biomarkers in 114 IRD patients from the PSARA study before and after 6 weeks and 6 months of treatment with methotrexate (MTX) or anti-tumor necrosis factor alpha (anti-TNF) therapy with or without MTX co-medication. Read More

    Routine Laboratory Parameter Dynamics and Laboratory Adverse Events in Psoriasis Patients on Long-term Treatment with Adalimumab, Etanercept, and Ustekinumab.
    Acta Derm Venereol 2017 Feb 22. Epub 2017 Feb 22.
    Department of Dermatology, University Hospital Heidelberg, DE-69115 Heidelberg, Germany.
    Only limited data on laboratory parameter dynamics and safety under prolonged biologic treatment in a "real-world" scenario are available for recommendations on screening and monitoring. This study is a retrospective analysis of routine parameter dynamics and laboratory adverse events (LAE) in psoriasis patients on long-term treatment (n = 199) with tumour necrosis factor (TNF)-α-antagonists (adalimumab, etanercept), and the interleukin (IL)12/23-antagonist ustekinumab. Overall, neutrophil (PMN) counts (-11%) and triglycerides (+9%) changed considerably. Read More

    Could Psoriatic Arthritis Be Easily Diagnosed from Current Suspicious Physical Findings in the Dermatology Clinic?
    Ann Dermatol 2017 Feb 3;29(1):48-54. Epub 2017 Feb 3.
    Department of Dermatology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
    Background: The prevalence and clinical characteristics of psoriatic arthritis (PsA) in patients with psoriasis are not well described in Asian populations, including Koreans.

    Objective: The purpose of this study was to investigate the prevalence of PsA by using the classification of psoriatic arthritis (CASPAR) criteria on the basis of physical examination only, as well as its correlation with psoriasis severity and other medical conditions including nail psoriasis.

    Methods: A single-center, cross-sectional observational cohort study was conducted, and the included patients were evaluated for PsA according to the CASPAR criteria. Read More

    TCD4(pos) lymphocytosis in rheumatoid and psoriatic arthritis patients following TNFα blocking agents.
    J Transl Med 2017 Feb 21;15(1):38. Epub 2017 Feb 21.
    Department of Clinical and Molecular Medicine, S. Andrea University Hospital, School of Medicine and Psychology, "Sapienza" University, Via di Grottarossa 1039, 00189, Rome, Italy.
    Background: Lymphocyte expansion and true lymphocytosis are commonly observed in the everyday clinical practice. The meaning of such phenomenon is often poorly understood so that discrimination between benign and malignant lymphocytosis remains difficult to establish. This is mainly true when lymphocytosis rises in patients affected by immune-mediated chronic inflammatory diseases under immunosuppressive treatment, conditions potentially associated with lymphomagenesis. Read More

    Psoriasis and associated variables in classification and outcome of juvenile idiopathic arthritis - an eight-year follow-up study.
    Pediatr Rheumatol Online J 2017 Feb 22;15(1):13. Epub 2017 Feb 22.
    Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
    Background: To study the impact of psoriasis and features associated with psoriasis on classification and outcome in a population-based follow-up cohort of children with juvenile idiopathic arthritis (JIA).

    Methods: In all, 440 children with JIA were followed for a median of 8 years in a prospective Nordic population-based cohort study. Data for remission was available for 427 of these children. Read More

    Incident myocardial infarction associated with major types of arthritis in the general population: a systematic review and meta-analysis.
    Ann Rheum Dis 2017 Feb 20. Epub 2017 Feb 20.
    Division of Epidemiology, University of Toronto Dalla Lana School of Public Health, Toronto, Ontario, Canada.
    Objective: To synthesise, quantify and compare risks for incident myocardial infarction (MI) across five major types of arthritis in population-based studies.

    Methods: A systematic search was performed in MEDLINE, EMBASE and CINAHL databases with additional manual/hand searches for population-based cohort or case-control studies published in English of French between January 1980 and January 2015 with a measure of effect and variance for associations between incident MI and five major types of arthritis: rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), gout or osteoarthritis (OA), adjusted for at least age and sex. All search screening, data abstraction quality appraisals were performed independently by two reviewers. Read More

    Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
    Semin Arthritis Rheum 2017 Jan 18. Epub 2017 Jan 18.
    Rheumatology Unit, Department of Emergence Medicine and Transplantation (DETO), University of Bari, Piazza G Cesare, 11, 70124 Bari, Italy.
    Objectives: To assess the drug survival of golimumab, and predictors thereof, in patients affected with rheumatoid arthritis (RA), spondyloarthritis (SpA), and psoriatic arthritis (PsA) in a prospective observational cohort.

    Methods: This is a non-interventional, longitudinal study on RA, SpA, and PsA patients starting treatment with golimumab. Endpoints were the 2 years persistence rate of golimumab and predictors of therapy discontinuation. Read More

    Frequency of concomitant fibromyalgia in rheumatic diseases: Monocentric study of 691 patients.
    Semin Arthritis Rheum 2017 Jan 18. Epub 2017 Jan 18.
    Rheumatology Department, CHU Gabriel-Montpied, Clermont-Ferrand, France. Electronic address:
    Objective: Fibromyalgia (FM) is a confounding factor for diagnosing and assessing rheumatic disease activity. This study sought to assess the extent of this syndrome in rheumatism patients at a French rheumatology department.

    Method: This monocentric epidemiological study enrolled all patients consulting due to rheumatoid arthritis (RA), spondyloarthritis (SpA), or connective tissue disease (CTD). Read More

    Variable selection and prediction in biased samples with censored outcomes.
    Lifetime Data Anal 2017 Feb 18. Epub 2017 Feb 18.
    Department of Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, N2L 3G1, Canada.
    With the increasing availability of large prospective disease registries, scientists studying the course of chronic conditions often have access to multiple data sources, with each source generated based on its own entry conditions. The different entry conditions of the various registries may be explicitly based on the response process of interest, in which case the statistical analysis must recognize the unique truncation schemes. Moreover, intermittent assessment of individuals in the registries can lead to interval-censored times of interest. Read More

    Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
    Drugs 2017 Feb 18. Epub 2017 Feb 18.
    Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
    Apremilast (Otezla(®)) is an orally administered, small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast 30 mg twice daily reduced the severity of moderate to severe plaque psoriasis in the phase 3 ESTEEM trials, as well as improving difficult-to-treat nail, scalp and palmoplantar psoriasis. Most patient-reported outcomes, including pruritus and the total Dermatology Life Quality Index, also improved to a significantly greater extent with apremilast than with placebo, with significant improvements in pruritus and skin discomfort/pain visual analogue scale scores seen as early as week 2 with apremilast. Read More

    Anti-TNF-induced remission in very early peripheral spondyloarthritis: the CRESPA study.
    Ann Rheum Dis 2017 Feb 17. Epub 2017 Feb 17.
    Department of Rheumatology, Ghent University Hospital, Ghent, Belgium.
    Objective: To evaluate the efficacy and safety of golimumab to induce clinical remission in patients with very early, active peripheral spondyloarthritis (pSpA).

    Methods: Clinical REmission in peripheral SPondyloArthritis is a monocentric study of golimumab treatment in patients with pSpA. All patients fulfilled the Assessment of SpondyloArthritis international Society classification criteria for pSpA, with a symptom duration ≤12 weeks. Read More

    Psoriasis and comorbid diseases: Implications for management.
    J Am Acad Dermatol 2017 Mar;76(3):393-403
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
    As summarized in the first article in this continuing medical education series, the currently available epidemiologic data suggest that psoriasis may be a risk factor for cardiometabolic disease. Emerging data also suggest associations between psoriasis and other comorbidities beyond psoriatic arthritis, including chronic kidney disease, inflammatory bowel disease, hepatic disease, certain malignancies, infections, and mood disorders. Recognizing the comorbid disease burden of psoriasis is essential for ensuring comprehensive care of patients with psoriasis. Read More

    Psoriasis and comorbid diseases: Epidemiology.
    J Am Acad Dermatol 2017 Mar;76(3):377-390
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Department of Epidemiology and Biostatistics, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
    Psoriasis is a common chronic inflammatory disease of the skin that is increasingly being recognized as a systemic inflammatory disorder. Psoriatic arthritis is a well-known comorbidity of psoriasis. A rapidly expanding body of literature in various populations and settings supports additional associations between psoriasis and cardiometabolic diseases, gastrointestinal diseases, kidney disease, malignancy, infection, and mood disorders. Read More

    Recovery of nail dystrophy potential new therapeutic indication of tofacitinib.
    Clin Rheumatol 2017 Feb 16. Epub 2017 Feb 16.
    Hospital Israelita Albert Einstein, Hospital AACD, São Paulo, Brazil.
    Nail dystrophy is a heterogeneous skin condition and in some subtypes, is associated with autoimmune diseases in particular psoriasis and psoriatic arthritis. In this report, we show that tofacitinib, a novel therapy for rheumatoid arthritis, appears to be beneficial in patients with nail disease refractory to other conventional modes of therapy. Read More

    Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?
    J Clin Exp Dent 2017 Feb 1;9(2):e325-e328. Epub 2017 Feb 1.
    DDS, MSc, PhD, Professor, Department of Oral Medicine and Pathology, Faculty of Dentistry, National and Kapodistrian University of Athens, Athens, Greece.
    Leflunomide is a member of the disease modifying anti-rheumatic drugs group used as a treatment modality in active rheumatoid and psoriatic arthritis. "Oral ulcers" are reported in 3-5% of leflunomide medicated rheumatoid arthritis patients with adverse events, but they are not described in detail in the literature. We present a case of an ulcer in the tongue of a rheumatoid arthritis patient managed with leflunomide and contemplate on its pathogenesis. Read More

    Inhibition of phosphodiesterase 4 (PDE4) reduces dermal fibrosis by interfering with the release of interleukin-6 from M2 macrophages.
    Ann Rheum Dis 2017 Feb 16. Epub 2017 Feb 16.
    Department of Internal Medicine 3, Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany.
    Objectives: To investigate the disease-modifying effects of phosphodiesterase 4 (PDE4) inhibition in preclinical models of systemic sclerosis (SSc).

    Methods: We studied the effects of PDE4 inhibition in a prevention and a treatment model of bleomycin-induced skin fibrosis, in the topoisomerase mouse model as well as in a model of sclerodermatous chronic graft-versus-host disease. To better understand the mode of action of PDE4 blockade in preclinical models of SSc, we investigated fibrosis-relevant mediators in fibroblasts and macrophages from healthy individuals and patients suffering from diffuse-cutaneous SSc on blockade of PDE4. Read More

    The Association Between Obesity and Clinical Features of Psoriatic Arthritis: A Case-control Study.
    J Rheumatol 2017 Feb 15. Epub 2017 Feb 15.
    From the Division of Rheumatology, Women's College Research Institute, Women's College Hospital; Department of Medicine, University of Toronto; Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; Division of Dermatology, Toronto Western Hospital, Toronto, Ontario, Canada. Supported by The Krembil Foundation and The Arthritis Society Foundation Salary Award. Dr. Eder is supported by the Arthritis Society Salary Award. The Psoriatic Arthritis Program is funded in part by The Arthritis Society, the Canadian Institutes of Health Research, and the Krembil Foundation. L. Eder, MD, PhD, Division of Rheumatology, Women's College Research Institute, Women's College Hospital, and Department of Medicine, University of Toronto; F. Abji, MSc, Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; C.F. Rosen, MD, FRCPC, Division of Dermatology, Toronto Western Hospital; V. Chandran, MD, DM, PhD, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital; D.D. Gladman, MD, FRCPC, Department of Medicine, University of Toronto, and Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital. Address correspondence to Dr. L. Eder, Women's College Research Institute, Women's College Hospital, 76 Grenville St., Toronto, Ontario M5S 1B2, Canada. E-mail: Accepted for publication December 14, 2016.
    Objective: To assess whether obesity is associated with distinct psoriatic arthritis (PsA) features and whether it interacts with PsA HLA susceptibility alleles.

    Methods: Patients with early PsA were compared with patients with psoriasis without arthritis (PsC). The primary predictor was the body mass index (BMI) at the first visit to the clinic. Read More

    Psoriatic arthritis disease activity during pregnancy and the first-year postpartum.
    Semin Arthritis Rheum 2017 Jan 16. Epub 2017 Jan 16.
    Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Psoriatic Arthritis Program, Center for Prognostic Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada. Electronic address:
    Objectives: To evaluate disease activity in the joints and skin during pregnancy and the first-year postpartum in patients with psoriatic arthritis (PsA).

    Methods: Women with PsA who were pregnant between 1990 and 2015 with at least 1 clinic visit during pregnancy were identified from the Toronto PsA database. The course of joint and skin disease activity was defined by the following 5 states: improvement, worsening, stable low, stable high, or a mixed. Read More

    Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population-based cohort study.
    J Dermatol 2017 Feb 13. Epub 2017 Feb 13.
    Department of Dermatology, College of Medicine, University of Hanyang, Seoul, Korea.
    There is a lack of nationwide studies examining the epidemiology and comorbidities of psoriasis vulgaris (PsV) and psoriatic arthritis (PsA) in Asian populations. The purpose of this study is to determine the demographics of psoriasis in Korea along with the incidence of cerebro-cardiovascular (CV) comorbidities and to compare these risks between populations with PsA and with PsV. This cohort study identified 15 484 patients with psoriasis among 855 003 subjects in the Korean National Health Insurance Database from 2002 through 2010. Read More

    Development of three-dimensional prints of arthritic joints for supporting patients' awareness to structural damage.
    Arthritis Res Ther 2017 Feb 10;19(1):34. Epub 2017 Feb 10.
    Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Ulmenweg 18, 91054, Erlangen, Germany.
    Background: Rheumatoid arthritis (RA) and psoriatic arthritis (PsA) result in severe joint destruction and functional disability if left untreated. We aim to develop tools that help patients with RA and PsA to understand and experience the impact of inflammatory joint disease on the integrity of their (juxta-articular) bone and increase adherence to medical treatment. In this study, we used high-resolution peripheral quantitative computed tomography (HR-pQCT) to develop 3D prototypes of patients' finger joints. Read More

    Characteristics and risk profile of psoriasis patients included in the Czech national registry BIOREP and a comparison with other registries.
    Int J Dermatol 2017 Feb 9. Epub 2017 Feb 9.
    Department of Dermatovenereology, Charles University, Third Faculty of Medicine and Faculty Hospital of Kralovske Vinohrady, Prague, Czech Republic.
    Background: BIOREP is a Czech registry of psoriatic patients on biological treatment in a clinical setting. We describe the characteristics of patients with psoriasis at the time of enrollment and present comparisons with published data from other national registries.

    Methods: We analyzed the cohort of patients treated with biologics between May 2005 and May 2015. Read More

    Clinical Examination, Ultrasound and MRI Imaging of The Painful Elbow in Psoriatic Arthritis and Rheumatoid Arthritis: Which is Better, Ultrasound or MR, for Imaging Enthesitis?
    Rheumatol Ther 2017 Feb 8. Epub 2017 Feb 8.
    St. Luke's Hospital, Bradford Teaching NHS Foundation Trust, Bradford, UK.
    Introduction: The purpose of the current study was to examine the painful elbow, and in particular enthesitis, in psoriatic arthritis (PsA) and rheumatoid arthritis (RA) using clinical examination, ultrasonography (US) and magnetic resonance imaging (MRI).

    Methods: Patients with elbow pain (11 with PsA and 9 with RA) were recruited. Clinical examination, US and MRI studies were performed on the same day. Read More

    Prevalence, incidence, and associated co-morbidities of treated hypothyroidism. An update from a European population.
    Eur J Endocrinol 2017 Feb 8. Epub 2017 Feb 8.
    R Gnavi, Epidemiology Unit, ASL TO3, Grugliasco, Italy.
    Objective: Estimates of the prevalence of hypothyroidism in unselected populations date from the late 1990s. We present an update on the prevalence and incidence of overt hypothyroidism in Piedmont, northwest Italy, and examine the association between hypothyroidism and multiple chronic comorbidities.

    Design And Methods: Data were obtained from drug prescription and hospital discharge databases. Read More

    Legionella pneumophila pneumonia possibly due to ustekinumab therapy in a patient with Crohn's disease.
    Am J Health Syst Pharm 2017 Feb;74(4):209-212
    Internal Medicine Division, Hospital de Sagunto, Sagunto, Spain.
    Purpose: A case report of Legionella pneumophila pneumonia associated with off-label use of ustekinumab in a patient with Crohn's disease (CD) is presented.

    Summary: A 57-year-old man with longstanding CD was hospitalized with a four-day history of fever (38.5 °C), dyspnea, left pleuritic pain, and weight loss (more than 6 kg) about six weeks after beginning treatment with ustekinumab, a human monoclonal antibody approved in the United States for two indications (plaque psoriasis and psoriatic arthritis) and currently under investigation as a potential treatment for CD and other inflammatory disorders. Read More

    Comorbidities in Patients with Psoriatic Arthritis.
    Rambam Maimonides Med J 2017 Jan 30;8(1). Epub 2017 Jan 30.
    Rheumatology Unit, Carmel Medical Centre, Haifa, Israel.
    Epidemiological studies have shown that patients with psoriatic arthritis (PsA) are often affected by numerous comorbidities that carry significant morbidity and mortality. Reported comorbidities include diabetes mellitus, obesity, metabolic syndrome, cardiovascular diseases, osteoporosis, inflammatory bowel disease, autoimmune eye disease, non-alcoholic fatty liver disease, depression, and fibromyalgia. All health care providers for patients with PsA should recognize and monitor those comorbidities, as well as understand their effect on patient management to ensure an optimal clinical outcome. Read More

    Psoriasis in systemic lupus erythematosus: a single-center experience.
    Clin Rheumatol 2017 Feb 6. Epub 2017 Feb 6.
    Centre for Prognosis Studies in the Rheumatic Diseases Toronto Western Hospital, University of Toronto Lupus Clinic, University Health Network, 399 Bathurst St. 1E-410B, Toronto, ON, M5T 2S8, Canada.
    The coexistence of psoriasis with systemic lupus erythematosus (SLE) has been reported in limited case series, raising hypotheses about shared pathogenetic mechanisms. Nevertheless, important differences regarding treatment do exist. The aim of the present study was to determine the prevalence and characteristics of psoriasis in a defined cohort of lupus patients. Read More

    A comparison of three treatment strategies in recent onset non-systemic Juvenile Idiopathic Arthritis: initial 3-months results of the BeSt for Kids-study.
    Pediatr Rheumatol Online J 2017 Feb 6;15(1):11. Epub 2017 Feb 6.
    Department of Pediatrics/Pediatric Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
    Background: Combination therapy with prednisone or etanercept may induce earlier and/or more improvement in disease activity in Disease Modifying Anti Rheumatic Drug (DMARD) naïve non-systemic Juvenile Idiopathic Arthritis (JIA) patients. Here we present three months clinical outcome of initial treatments of the BeSt-for-Kids study.

    Methods: Included patients were randomized to either: 1. Read More

    The role of IL 23 in the treatment of psoriasis.
    Expert Rev Clin Immunol 2017 Feb 6. Epub 2017 Feb 6.
    a Dept. of Dermatology, Hospital de la Santa Creu i Sant Pau , Universitat Autònoma de Barcelona , Sant Quintí 89, 08041 Barcelona , Catalonia , Spain.
    Introduction: The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis. Human IL-23 is primarily produced by antigen-presenting cells and induces and maintains differentiation of Th17 cells and Th22 cells, a primary cellular source of proinflammatory cytokines such as IL-17 and IL-22, which mediate the epidermal hyperplasia, keratinocyte immune activation and tissue inflammation inherent in psoriasis. Agents that target the p40 subunit common to both IL-12 and IL-23 have shown robust clinical activity, but selectivity for IL-23p19 could offer advantages in efficacy and safety with respect to anti-p40 blockade. Read More

    Certolizumab pegol for the treatment of psoriasis.
    Expert Opin Biol Ther 2017 Mar 6;17(3):387-394. Epub 2017 Feb 6.
    a Dermatological Clinic, Department of Clinical and Molecular Sciences , Polytechnic Marche University , Ancona , Italy.
    Introduction: Psoriasis is a chronic immunomediated and inflammatory disease involving mainly skin and joints, often associated with several metabolic and non-metabolic comorbidities. TNF-alpha inhibitors have shown long-term efficacy and safety/tolerability in psoriasis, and preliminary data support the use of certolizumab pegol (CZP) as well. Areas covered: The authors review the pharmacological properties of CZP, as well as its safety data and efficacy profile. Read More

    Cause-specific mortality in patients with psoriatic arthritis and rheumatoid arthritis.
    Rheumatology (Oxford) 2017 Jan 31. Epub 2017 Jan 31.
    Department of Dermatology, Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.

    Subjective Health Complaints in Individuals with Psoriasis and Psoriatic Arthritis: Associations with the Severity of the Skin Condition and Illness Perceptions - A Cross-Sectional Study.
    Int J Behav Med 2017 Feb 2. Epub 2017 Feb 2.
    Department of Public Health Science, Faculty of Landscape and Society, Norwegian University of Life Science, PO Box 5003, NO-1432, Ås, Norway.
    Purpose: High comorbidity has been reported among persons with psoriasis and psoriatic arthritis (PsA), but the occurrence of subjective health complaints (SHCs) in these patient groups is poorly understood. The study aimed to describe the prevalence of SHCs among individuals with psoriasis and PsA in Norway, and investigate whether the severity of their skin condition and their illness perceptions were associated with the number and severity of health complaints.

    Method: Participants were recruited through the Psoriasis and Eczema Association of Norway (PEF) (n = 942). Read More

    Does non-adherence to DMARDs influence hospital-related healthcare costs for early arthritis in the first year of treatment?
    PLoS One 2017 2;12(2):e0171070. Epub 2017 Feb 2.
    Department of Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands.
    Introduction: Non-adherence to disease-modifying antirheumatic drugs (DMARDs) is suspected to relate to health care costs. In this study we investigated this relation in the first year of treatment.

    Methods: In a multi-center cohort study with a one year follow up, non-adherence was continuously measured using electronic monitored medication jars. Read More

    Non-pharmacological and pharmacological interventions in patients with early arthritis: a systematic literature review informing the 2016 update of EULAR recommendations for the management of early arthritis.
    RMD Open 2017 5;3(1):e000404. Epub 2017 Jan 5.
    Department of Clinical Immunology & Rheumatology , Amsterdam Rheumatology Center, Amsterdam & Zuyderland Medical Centre , Heerlen , The Netherlands.
    Objective: To perform a systematic literature review (SLR) on pharmacological and non-pharmacological treatments, in order to inform the European League Against Rheumatism (EULAR) recommendations for the management of early arthritis (EA).

    Methods: The expert committee defined research questions concerning non-pharmacological interventions, patient information and education, non-steroidal anti-inflammatory drug, glucocorticoid (GC) and disease-modifying antirheumatic drugs (DMARDs) use, as well as on disease monitoring. The SLR included articles published after the last EULAR SLR until November 2015 found in the MEDLINE, EMBASE and Cochrane databases and abstracts from the 2014 and 2015 American College of Rheumatology and EULAR conferences. Read More

    Evaluation of Serum Fetuin-A and Osteoprotegerin Levels in Patients with Psoriasis.
    Indian J Clin Biochem 2017 Mar 6;32(1):90-94. Epub 2016 May 6.
    0000 0001 2033 6079grid.411822.cDepartment of Biochemistry, Faculty of Medicine, Bulent Ecevit University, Zonguldak, Turkey.
    Psoriasis patients are determined to have a high ratio of coronary artery calcification. Fetuin-A and osteoprotegerin are systemic calcification inhibitors and related to vascular calcification and cardiovascular mortality. In this study we investigated the relationship between fetuin-A and osteoprotegerin levels in psoriasis patients. Read More

    Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
    J Rheumatol 2017 Feb 1. Epub 2017 Feb 1.
    From the Department of Rheumatology, Hospital of Southern Norway Trust, Kristiansand; Department of Rheumatology, Haugesund Rheumatism Hospital, Haugesund, Norway; Division of Rheumatology, Allergy, Immunology, University of California at San Diego, San Diego, California, USA; Department of Rheumatology, Martina Hansens Hospital, Bærum; Norwegian University of Science and Technology, Trondheim, Norway. Funded by an unrestricted grant from Pfizer (GH). Clinical research fellowship from the Hospital of Southern Norway Trust (BM). B. Michelsen, MD, Department of Rheumatology, Hospital of Southern Norway Trust; A.P. Diamantopoulos, PhD, Department of Rheumatology, Haugesund Rheumatism Hospital; H.K. Høiberg, MD, Department of Rheumatology, Hospital of Southern Norway Trust; D.M. Soldal, MD, Department of Rheumatology, Hospital of Southern Norway Trust; A. Kavanaugh, PhD, Division of Rheumatology, Allergy, Immunology, University of California at San Diego; G. Haugeberg, PhD, Department of Rheumatology, Hospital of Southern Norway Trust, and Department of Rheumatology, Martina Hansens Hospital, and Norwegian University of Science and Technology. Address correspondence to Dr. B. Michelsen, Department of Rheumatology, Hospital of Southern Norway Trust, Service box 416, 4604 Kristiansand, Norway. E-mail: Accepted for publication December 5, 2016.
    Objective: To explore the burden of skin, joint, and entheses manifestations in a representative psoriatic arthritis (PsA) outpatient cohort in the biologic treatment era.

    Methods: This was a cross-sectional study of 141 PsA outpatients fulfilling the ClASsification for Psoriatic ARthritis (CASPAR) criteria and examined between January 2013 and May 2014. Selected disease activity measures were explored including Disease Activity index for PSoriatic Arthritis (DAPSA), Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Disease Activity Score (PASDAS), Disease Activity Score for 28 joints (DAS28), Simplified Disease Activity Index (SDAI), and Psoriasis Area Severity Index (PASI). Read More

    The Juvenile Psoriatic Arthritis Cohort in the CARRA Registry: Clinical Characteristics, Classification, and Outcomes.
    J Rheumatol 2017 Feb 1. Epub 2017 Feb 1.
    From the Department of Rheumatology, and the Department of Community Medicine and Epidemiology, Carmel Medical Center, Haifa, Israel; The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Haifa, Israel; Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario, Canada; Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama; Department of Medicine, and Department of Pediatrics, Division of Immunology and Rheumatology, Stanford University, Palo Alto, California; Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University, Palo Alto, California, USA. Supported by the Feldman Family Foundation Visiting Professors Program, Stanford University School of Medicine (to DZ), and the Arthritis Foundation Western Region Center of Excellence for Arthritis (to EDM). The CARRA Legacy Registry was supported by grants from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases, Friends of CARRA, the Arthritis Foundation, and the US National Institutes of Health (RC2AR058934). D. Zisman, MD, Department of Rheumatology, Carmel Medical Center, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion; D.D. Gladman, MD, FRCPC, Psoriatic Arthritis Program, Centre for Prognosis Studies in The Rheumatic Diseases, Toronto Western Hospital; M.L. Stoll, MD, PhD, MSCS, Department of Pediatrics, Division of Rheumatology, University of Alabama at Birmingham; V. Strand, MD, FACP, FACR, Department of Medicine, Division of Immunology and Rheumatology, Stanford University; I. Lavi, MA, Department of Community Medicine and Epidemiology, Carmel Medical Center; J.J. Hsu, MD, Department of Pediatrics, Division of Allergy, Immunology and Rheumatology, Stanford University; E.D. Mellins, MD, Department of Pediatrics, Divisions of Human Gene Therapy and Allergy, Immunology and Rheumatology, Program in Immunology, Stanford University. Dr. Gladman, Dr. Stoll, and Dr. Strand contributed equally to this paper and are listed alphabetically. Address correspondence to Dr. D. Zisman, Department of Rheumatology, Carmel Medical Center, 7 Michal St., Haifa 34362, Israel. E-mail: Accepted for publication November 29, 2016.
    Objective: Children with clinically diagnosed juvenile psoriatic arthritis (JPsA) who were enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) registry (CARRA-JPsA) were classified according to pediatric International League of Associations for Rheumatology (ILAR) and adult criteria [Classification criteria for Psoriatic Arthritis (CASPAR)]. Data on demographic and clinical features at baseline and 1-year followup were analyzed and compared.

    Methods: Cross-sectional analysis was performed of CARRA-JPsA patients enrolled between May 2010 and December 2013 and stratified according to age at disease onset (≤ or > 4 yrs). Read More

    Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016.
    J Rheumatol 2017 Feb 1. Epub 2017 Feb 1.
    From the Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Rheumatology Research, Swedish Medical Center and University of Washington School of Medicine, Seattle, Washington; Department of Dermatology, University of Utah, Salt Lake City, Utah; Quintiles, Duke University School of Medicine, Durham, North Carolina; Division of Immunology, Stanford University, Palo Alto, California; Cleveland Clinic, Cleveland, Ohio; University of Pennsylvania, Philadelphia, Pennsylvania, USA; VU Medical Centre, Amsterdam; Department of Rheumatology, Leiden University Medical Center, Leiden, the Netherlands; Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland; Royal National Hospital for Rheumatic Diseases; Royal National Hospital for Rheumatic Diseases, Bath; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals UK National Health Service (NHS) Trust, Leeds, UK; Toronto Western Hospital; University of Toronto; Krembil Research Institute; Psoriatic Arthritis Program, University Health Network; Women's College Research Institute, Women's College Hospital, University of Toronto, Toronto; Ottawa Hospital Research Institute, School of Epidemiology, Public Health and Preventative Medicine, University of Ottawa, Ottawa, Ontario, Canada; Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology, Paris, France; The Parker Institute, Bispebjerg and Frederiksberg Hospital, Frederiksberg, Denmark; Department of Rheumatology and Immunology, Singapore General Hospital, Singapore; Department of Internal Medicine, Division of Rheumatology, Hacettepe University, Ankara, Turkey. AMO was supported in part by a Scientist Development Award from the Rheumatology Research Foundation and the Johns Hopkins Arthritis Center Discovery Fund. AO was supported by research grant K23 AR063764 from the US National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). This work was supported in part by research grant P30-AR053503 (RDRCC Human Subjects Research Core) from NIAMS and the Camille J. Morgan Arthritis Research and Education Fund. The international focus group study was supported by research grants from Celgene and Janssen. The nominal group technique meeting was supported by research grants from AbbVie, Celgene, and Pfizer. The UK focus group study was funded by the National Institute for Health Research (Programme Grants for Applied Research, Early detection to improve outcome in patients with undiagnosed psoriatic arthritis, RP-PG-1212-20007). Attendance of working group fellows and patient research partners to the Outcome Measures in Rheumatology (OMERACT) conference was supported with workshop funds from Group for Research and Assessment of Psoriasis and Psoriatic Arthritis and OMERACT. A.M. Orbai, MD, MHS, Division of Rheumatology, Johns Hopkins University School of Medicine; M. de Wit, PhD, Patient Research Partner, VU Medical Centre; P.J. Mease, MD, Rheumatology Research, Swedish Medical Center, and University of Washington School of Medicine; K. Callis Duffin, MD, Department of Dermatology, University of Utah; M. Elmamoun, MBBS, MRCPI, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; W. Tillett, BSc, MB ChB, PhD, MRCP, Royal National Hospital for Rheumatic Diseases; W. Campbell, BEd LLB, Patient Research Partner, Toronto Western Hospital; O. FitzGerald, MD, FRCPI, FRCP(UK), Newman Clinical Research Professor, Department of Rheumatology, St. Vincent's University Hospital, and Conway Institute for Biomolecular Research, University College Dublin; D.D. Gladman, MD, FRCPC, Professor of Medicine, University of Toronto, and Senior Scientist, Krembil Research Institute, and Director, Psoriatic Arthritis Program, University Health Network; N. Goel, MD, Patient Research Partner, Quintiles, Duke University School of Medicine; L. Gossec, MD, PhD, Sorbonne Universités, UPMC Univ Paris 06, Institut Pierre Louis d'Epidémiologie et de Santé Publique, GRC-UPMC 08 (EEMOIS), and AP-HP, Pitié Salpêtrière Hospital, Department of Rheumatology; P. Hoejgaard, MD, The Parker Institute, Bispebjerg and Frederiksberg Hospital; Y.Y. Leung, MD, PhD, Department of Rheumatology and Immunology, Singapore General Hospital; C.A. Lindsay, PharmD, Patient Research Partner; V. Strand, MD, Division of Immunology, Stanford University; D.M. van der Heijde, MD, PhD, Department of Rheumatology, Leiden University Medical Center; B. Shea, MSc, PhD, Senior Methodologist, Ottawa Hospital Research Institute, Adjunct Professor, School of Epidemiology, Public Health and Preventative Medicine, Faculty of Medicine, University of Ottawa; R. Christensen, BSc, MSc, PhD, Head of Unit, Professor of Clinical Epidemiology, Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg Hospital; L. Coates, MB ChB, PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust; L. Eder, MD, PhD, Women's College Research Institute, Women's College Hospital, University of Toronto; N. McHugh, MBChB, MD, FRCP, FRCPath, Royal National Hospital for Rheumatic Diseases; U. Kalyoncu, MD, Department of Internal Medicine, Division of Rheumatology, Hacettepe University; I. Steinkoenig, BA, Patient Research Partner, Cleveland Clinic; A. Ogdie, MD, MSCE, University of Pennsylvania. Address correspondence to Dr. A.M. Orbai, Johns Hopkins Arthritis Center, 5501 Hopkins Bayview Circle, AAC-1B, Baltimore, Maryland 21224, USA. E-mail: Full Release Article. For details see Reprints and Permissions at jrheum.org. Accepted for publication December 20, 2016.
    Objective: To include the patient perspective in accordance with the Outcome Measures in Rheumatology (OMERACT) Filter 2.0 in the updated Psoriatic Arthritis (PsA) Core Domain Set for randomized controlled trials (RCT) and longitudinal observational studies (LOS).

    Methods: At OMERACT 2016, research conducted to update the PsA Core Domain Set was presented and discussed in breakout groups. Read More

    1 OF 160